Filing Flows › Comparisons › GKOS vs NVCR
Glaukos vs NovoCure: GKOS and NVCR compared
Glaukos is the larger company: $211M of revenue in its latest quarter (Q3 2026) against $193M for NovoCure (Q3 2026). Glaukos is growing faster (+58% against +16% a year earlier). Glaukos is more profitable, with an operating margin of 0.4% against -3.2%.
Where the money goes: GKOS and NVCR
Glaukos (GKOS) · Q3 2026
Glaukos, Q3 2026: revenue $211M (+58% year over year), operating margin 0.4%, net earnings $2.0M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
NovoCure (NVCR) · Q3 2026
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
| Glaukos (GKOS) | NovoCure (NVCR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $211M | $193M |
| Revenue growth, Y/Y | +58% | +16% |
| Gross margin | 85.2% | — |
| Operating margin | 0.4% | -3.2% |
| Net earnings | $2.0M | −$10.4M |
| Net margin | 1.0% | -5.4% |
| Operating cash flow | $38.6M | $22.7M |
| Free cash flow | $36.5M | $15.7M |
| Market value | $11.1B | — |
| Analysts’ mean target | $242.46 | — |
Where the revenue comes from
Glaukos
- Glaucoma: $152M (72%)
- Corneal Health: $59.0M (28%)
Questions
Which is bigger, Glaukos or NovoCure?
Glaukos is the larger company: $211M of revenue in its latest quarter (Q3 2026) against $193M for NovoCure (Q3 2026).
Is Glaukos or NovoCure growing faster?
Glaukos is growing faster (+58% against +16% a year earlier).
Which is more profitable, Glaukos or NovoCure?
Glaukos is more profitable, with an operating margin of 0.4% against -3.2%.
More: Glaukos earnings · how Glaukos makes money · NovoCure earnings · how NovoCure makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 28, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.